ArticleEmerging microbes & infections2020
Identifying optimal capsid duplication length for the stability of reporter flaviviruses.
Article in Emerging microbes & infections, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 32 citations in OpenAlex.
- GC content mismatch of transgene destabilizes RNA virus genomes.Journal of virology · 2026Article
- 1'- and 4'-Cyano Modified Adenosine Analogs Against Prototypic Flavivirus RNA-Dependent RNA Polymerases.Viruses · 2026Article
- Application of Orthoflavivirus Pseudovirus Technology in Antiviral Research.International journal of molecular sciences · 2026Review
- A dual-reporter HCoV-OC43 for coronavirus biology and countermeasure development.Antiviral research · 2025Article
- Fluorescence-based biosensors for West Nile virus detection.Virulence · 2025Article
- Japanese Encephalitis Virus Genotype 5 Infectious Clone and Reporter System for Antiviral Evaluation.Journal of medical virology · 2025Article
- Enantioselective Chemical Probe for Chikungunya nsP2 Helicase with Antialphaviral Activity.ACS infectious diseases · 2025Article
- Mechanistic insights into dengue virus inhibition by a clinical trial compound NITD-688.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Druggable genome screens identify SPP as an antiviral host target for multiple flaviviruses.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Reporter-expressing viruses for antiviral drug discovery research.Frontiers in cellular and infection microbiology · 2025Review
- The Dynamic Landscape of Capsid Proteins and Viral RNA Interactions in Flavivirus Genome Packaging and Virus Assembly.Pathogens (Basel, Switzerland) · 2024Review
- Expanded profiling of Remdesivir as a broad-spectrum antiviral and low potential for interaction with other medications in vitro.Scientific reports · 2023Article
- Validation of flavivirus infectious clones carrying fluorescent markers for antiviral drug screening and replication studies.Frontiers in microbiology · 2023Article
- A Recombinant Genotype I Japanese Encephalitis Virus Expressing aInternational journal of molecular sciences · 2022Article
- Reporter Flaviviruses as Tools to Demonstrate Homologous and Heterologous Superinfection Exclusion.Viruses · 2022Article
- Article
- Tracking the Replication-Competent Zika Virus with Tetracysteine-Tagged Capsid Protein in Living Cells.Journal of virology · 2022Article
- Generation and Application of a Luciferase Reporter Virus Based on Yellow Fever Virus 17D.Virologica Sinica · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.